Vertex Pharmaceuticals Inc
Close on Nov 19, 2026Market cap $131.97BP/E 30.3Yield –
Vertex Pharmaceuticals Net product revenues — Total by Quarter
Net product revenues — Total ($M) ($M)
Vertex Pharmaceuticals Net product revenues — Total: $3,334M in Q2 2026, up 13.2% from a year earlier. That is the highest of the 34 quarters on record here.
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-04) ↗
Reported in Form 10-Q / 10-K Revenue Disaggregation Note & Form 8-K.
quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Net product revenues — Total ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 3,334 | +13.2% | Form 10-Q (filed 2026-08-04) ↗ |
| Q1 2026 | Mar 31, 2026 | 2,987 | +8.2% | Form 10-Q (filed 2026-05-05) ↗ |
| Q4 2025 | Dec 31, 2025 | 3,190 | +9.5% | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2025 | Sep 30, 2025 | 3,076 | +11.0% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2025 | Jun 30, 2025 | 2,944 | +11.3% | Form 10-Q (filed 2026-08-04) ↗ |
| Q1 2025 | Mar 31, 2025 | 2,760 | +2.6% | Form 10-Q (filed 2026-05-05) ↗ |
| Q4 2024 | Dec 31, 2024 | 2,912 | – | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2024 | Sep 30, 2024 | 2,772 | – | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2024 | Jun 30, 2024 | 2,646 | – | Form 10-Q (filed 2025-08-05) ↗ |
| Q1 2024 | Mar 31, 2024 | 2,691 | – | Form 10-Q (filed 2025-05-06) ↗ |
| Q4 2022 | Dec 31, 2022 | 2,303 | +11.1% | Form 10-K (filed 2024-02-15) ↗ |
| Q3 2022 | Sep 30, 2022 | 2,334 | +17.7% | Form 10-Q (filed 2022-10-28) ↗ |
| Q2 2022 | Jun 30, 2022 | 2,196 | +22.5% | Form 10-Q (filed 2022-08-05) ↗ |
| Q1 2022 | Mar 31, 2022 | 2,098 | +21.7% | Form 10-Q (filed 2022-05-06) ↗ |
| Q4 2021 | Dec 31, 2021 | 2,073 | +27.4% | Form 10-K (filed 2024-02-15) ↗ |
| Q3 2021 | Sep 30, 2021 | 1,984 | +29.1% | Form 10-Q (filed 2022-10-28) ↗ |
| Q2 2021 | Jun 30, 2021 | 1,793 | +17.6% | Form 10-Q (filed 2022-08-05) ↗ |
| Q1 2021 | Mar 31, 2021 | 1,723 | +13.7% | Form 10-Q (filed 2022-05-06) ↗ |
| Q4 2020 | Dec 31, 2020 | 1,627 | +15.1% | Form 10-K (filed 2021-02-11) ↗ |
| Q3 2020 | Sep 30, 2020 | 1,536 | +61.7% | Form 10-Q (filed 2021-11-03) ↗ |
| Q2 2020 | Jun 30, 2020 | 1,525 | +62.1% | Form 10-Q (filed 2021-07-30) ↗ |
| Q1 2020 | Mar 31, 2020 | 1,515 | +76.7% | Form 10-Q (filed 2021-04-30) ↗ |
| Q4 2019 | Dec 31, 2019 | 1,413 | +62.8% | Form 10-K (filed 2021-02-11) ↗ |
| Q3 2019 | Sep 30, 2019 | 950 | +21.4% | Form 10-K (filed 2021-02-11) ↗ |
| Q2 2019 | Jun 30, 2019 | 940 | +25.4% | Form 10-K (filed 2021-02-11) ↗ |
| Q1 2019 | Mar 31, 2019 | 857 | +34.4% | Form 10-K (filed 2021-02-11) ↗ |
| Q4 2018 | Dec 31, 2018 | 868 | +39.8% | Form 10-K (filed 2020-02-13) ↗ |
| Q3 2018 | Sep 30, 2018 | 783 | +42.4% | Form 10-K (filed 2020-02-13) ↗ |
| Q2 2018 | Jun 30, 2018 | 750 | +45.9% | Form 10-K (filed 2020-02-13) ↗ |
| Q1 2018 | Mar 31, 2018 | 638 | +32.7% | Form 10-K (filed 2020-02-13) ↗ |
| Q4 2017 | Dec 31, 2017 | 621 | – | Form 10-K (filed 2019-02-13) ↗ |
| Q3 2017 | Sep 30, 2017 | 550 | – | Form 10-K (filed 2019-02-13) ↗ |
| Q2 2017 | Jun 30, 2017 | 514 | – | Form 10-K (filed 2019-02-13) ↗ |
| Q1 2017 | Mar 31, 2017 | 481 | – | Form 10-K (filed 2019-02-13) ↗ |
Breakdown
What makes up net product revenues — Total
- TRIKAFTA / KAFTRIO (elexacaftor/tezacaftor/ivacaftor) — Net product revenues ($M)2,497 · Q2 2026
- ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) — Net product revenues ($M)574 · Q2 2026
- SYMDEKO / SYMKEVI (tezacaftor/ivacaftor) — Net product revenues (standalone through FY2023, $M)27.8 · Q4 2023
- ORKAMBI (lumacaftor/ivacaftor) — Net product revenues (standalone through FY2023, $M)44.2 · Q4 2023
- KALYDECO (ivacaftor) — Net product revenues (standalone through FY2023, $M)112 · Q4 2023
- CASGEVY (exagamglogene autotemcel) — Net product revenues ($M)76.4 · Q2 2026
- JOURNAVX (suzetrigine) — Net product revenues ($M)49.6 · Q2 2026
- Other product revenues (SYMDEKO/SYMKEVI, ORKAMBI, KALYDECO & other combined, $M)137 · Q2 2026
Cite this data
StockData. (2026). Vertex Pharmaceuticals Net product revenues — Total ($M), quarterly Q1 2017–Q2 2026 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/rev-product-total
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.
See a number that looks wrong?